Advances of study on PPARgamma/PPARgamma ligand in hematologic malignancies.
- Author:
Hai-Wen HUANG
1
;
De-Pei WU
Author Information
1. Department of Hematology, The First Hospital, Suzhou University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Hematologic Neoplasms;
metabolism;
pathology;
Humans;
Ligands;
PPAR gamma;
metabolism
- From:
Journal of Experimental Hematology
2009;17(6):1592-1596
- CountryChina
- Language:Chinese
-
Abstract:
Recently, along with the thorough investigation on the gene and molecular biology of peroxisome proliferators activated receptorgamma (PPARgamma), the therapeutic effects of PPARgamma ligand and its potential mechanism were gradually recognized. PPARgamma will probably become a new target of oncotherapy and is now extensively followed by researchers. This review focuses the advances of study on PPARgamma distribution in tissue, its function, its ligand in relationship with hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, lymphoma, multiple myeloma and so on.
